Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-7.20 Insider Own11.83% Shs Outstand4.48M Perf Week-1.80%
Market Cap7.35M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.95M Perf Month0.12%
Income-20.26M PEG- EPS next Q- Inst Own4.17% Short Float1.49% Perf Quarter17.14%
Sales0.02M P/S367.36 EPS this Y- Inst Trans28.33% Short Ratio0.54 Perf Half Y-67.00%
Book/sh0.23 P/B7.12 EPS next Y- ROA-258.71% Short Interest0.06M Perf Year-44.22%
Cash/sh0.46 P/C3.55 EPS next 5Y- ROE-314.88% 52W Range1.00 - 7.74 Perf YTD-70.85%
Dividend Est.- P/FCF- EPS past 5Y29.34% ROI-771.80% 52W High-78.81% Beta0.55
Dividend TTM- Quick Ratio2.69 Sales past 5Y-20.00% Gross Margin22.01% 52W Low64.00% ATR (14)0.24
Dividend Ex-Date- Current Ratio2.69 EPS Y/Y TTM-12.87% Oper. Margin-49380.41% RSI (14)44.35 Volatility8.53% 17.55%
Employees5 Debt/Eq0.05 Sales Y/Y TTM-84.54% Profit Margin-98219.66% Recom1.00 Target Price90.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q50.11% Payout- Rel Volume0.09 Prev Close1.69
Sales Surprise- EPS Surprise40.00% Sales Q/Q-100.00% Earnings- Avg Volume109.25K Price1.64
SMA20-20.78% SMA505.40% SMA200-45.53% Trades Volume10,131 Change-2.96%
May-22-24 08:00AM
May-17-24 08:00AM
May-16-24 12:52PM
May-15-24 01:07PM
08:00AM Loading…
May-07-24 08:00AM
Apr-19-24 05:50PM
Apr-01-24 09:05AM
Mar-18-24 07:00AM
Mar-17-24 08:38AM
Mar-05-24 07:45AM
Mar-01-24 04:04PM
Feb-27-24 09:25PM
Feb-12-24 04:41PM
08:00AM Loading…
Feb-07-24 08:00AM
Feb-05-24 08:00AM
Jan-23-24 05:34PM
Jan-02-24 07:30AM
Nov-10-23 09:19AM
Nov-02-23 07:00AM
Oct-18-23 08:30AM
Oct-05-23 06:30AM
Sep-29-23 04:00PM
Aug-14-23 02:46PM
Aug-07-23 08:30AM
Jun-05-23 04:18PM
May-12-23 06:32PM
Mar-29-23 11:45AM
08:30AM Loading…
Mar-14-23 08:30AM
Mar-08-23 09:09AM
Mar-01-23 01:47PM
Feb-03-23 07:30AM
Jan-30-23 02:24PM
Dec-23-22 04:05PM
Dec-22-22 07:30AM
Dec-20-22 04:36PM
Dec-19-22 04:34PM
Oct-24-22 04:01PM
Sep-30-22 07:30AM
Aug-24-22 07:00AM
Jun-23-22 04:30PM
Jun-14-22 07:30AM
May-17-22 07:30AM
May-13-22 04:17PM
Apr-18-22 07:30AM
Apr-06-22 07:30AM
Mar-25-22 07:30AM
Mar-22-22 08:59AM
Mar-10-22 07:30AM
Mar-03-22 09:09AM
Feb-07-22 01:45PM
Jan-26-22 07:30AM
Jan-14-22 05:38PM
Jan-04-22 12:02PM
Dec-20-21 12:08PM
Dec-09-21 08:00AM
Dec-08-21 08:00AM
Dec-01-21 08:00AM
Nov-23-21 08:30AM
Oct-04-21 07:30AM
Sep-15-21 11:01AM
Aug-31-21 09:15AM
Aug-30-21 10:06AM
Aug-24-21 07:30AM
Jul-27-21 07:00AM
Jul-12-21 10:10AM
Jul-01-21 07:00AM
May-18-21 07:30AM
May-03-21 07:30AM
Apr-09-21 10:50AM
Mar-09-21 12:09PM
Mar-08-21 07:30AM
Feb-12-21 08:00AM
Feb-02-21 08:00AM
Jan-14-21 07:00AM
Jan-07-21 07:00AM
Dec-29-20 04:00PM
Dec-24-20 08:30AM
Dec-02-20 09:37AM
Nov-24-20 11:37AM
Nov-20-20 08:30AM
Nov-19-20 05:14PM
Oct-06-20 07:30AM
Sep-28-20 07:30AM
Sep-11-20 07:30AM
Sep-03-20 09:47AM
Aug-20-20 08:30AM
Jul-22-20 07:30AM
Jul-10-20 07:30AM
Jun-04-20 08:00AM
Jun-03-20 09:00AM
May-19-20 08:01AM
May-08-20 05:45AM
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Telling FredDirectorNov 30 '23Sale3.573,50012,48838,345Dec 01 05:23 PM